Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Unknown 24Recruiting 19Not yet recruiting 15Completed 4Active not recruiting 3Suspended 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 3Thoracic 1

Conditions

Solid Tumors 2Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic Solid Tumors 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × envafolimab × Clear all
NCT05068427 2024-08-07

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Chipscreen Biosciences, Ltd.

Phase 2 Completed
34 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03101488 2022-03-03

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

3D Medicines

Phase 1 Completed
287 enrolled
Other solid neoplasm

Solid Tumors

NCT03248843 2022-02-08

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

3D Medicines

Phase 1 Completed
35 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT02827968 2021-06-02

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

3D Medicines

Phase 1 Completed
28 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡